This time, a memorandum of business cooperation was signed to prepare the two sides to expand commercialization of Yongtai products.
The Zhitong Finance App learned that on March 1, 2024, Yongtai Bio-B (06978) signed a memorandum of business cooperation with Corning in Beijing. Wang Wei, CEO of Yongtai Biotech, and Lin Chunmei, vice president of Corning and CEO of Corning Life Sciences Group Greater China, attended the signing ceremony.
As a leader in cellular immunotherapy in China, Yongtai Biotech has many collaborations with Corning. This time, a memorandum of business cooperation was signed to prepare the two sides to expand commercialization of Yongtai products. With the signing of the Memorandum of Business Cooperation, the two sides will carry out deeper cooperation in the development and marketing of customized products, testing laboratories, new products, etc., to promote the commercialization and implementation of Yongtai's important R&D pipelines.
This cooperation will be Yongtai Biotech's most important step towards “commercialization”: with Corning's products, Yongtai Biotech will promote preparations for large-scale commercial production, ensure standardization and scale of all aspects of production quality, accelerate the strategic process of commercialization of key products, continue to maintain and establish industry models, and promote product marketing as soon as possible to meet the needs of clinical patients.
Regarding this cooperation, Mr. Wang Yuwang, CEO of Yongtai Biotech, said: “We are very happy to reach a comprehensive and in-depth cooperation with Corning of the United States. As leading products in the field of cellular immunity, Corning's culture medium and automation solutions have a unique sense of innovation and industry best practices. We expect to lay a solid foundation for Yongtai Biotech to accelerate the launch of products and promote commercialization through the complementary advantages of both parties, and provide us with strong technical support to achieve the ultimate goal of curing tumors.
Lin Chunmei, vice president of Corning and CEO of Corning Life Sciences Group Greater China, said: “We are very happy to have reached a strategic cooperation with Yongtai Biotech. As a leader in the cell therapy industry, Yongtai Biotech has rich experience in the development, transformation and industrialization of cell therapy drugs. We look forward to promoting the marketing of Yongtai biological products by complementing the advantages of both parties to benefit patients sooner and better. Corning will work with Yongtai Biotech to establish a consistent action plan to promote product commercialization and improve the industrial base.